Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


LSKB’s Lead Project Set For Phase III Gastric Cancer Trial

This article was originally published in PharmAsia News

Executive Summary

During an investor relations meeting in Seoul, South Korea’s HLB talked about recent clinical R&D progress for the lead project at its subsidiary LSK BioPharma and its developing pipeline. LSK revealed it is set to begin global Phase III trials for apatinib in gastric cancer and also aims to move on to the clinical development of a newly licensed in BTK inhibitor within 2016.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts